期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.652470
关键词
viral infection; SARS-CoV-2; COVID-19; granulocytes; neutrophils; scRNA-seq; clinical trials
类别
资金
- Department of Genomics & Immunoregulation at the LIMES Institute
- ImmunoSensation2 Women in Science grant
- German Research Foundation (DFG) under Germany's Excellence Strategy [EXC2151 - 390873048]
- EU project SYSCID [733100]
- BMBF [01ZX1902B, 01EA1809A]
- ERA CVD [00160389]
Research has found that the immune deviation of neutrophils in COVID-19 patients and promising therapeutic attempts to target them are crucial for understanding and treating the disease.
Strong evidence has been accumulated since the beginning of the COVID-19 pandemic that neutrophils play an important role in the pathophysiology, particularly in those with severe disease courses. While originally considered to be a rather homogeneous cell type, recent attention to neutrophils has uncovered their fascinating transcriptional and functional diversity as well as their developmental trajectories. These new findings are important to better understand the many facets of neutrophil involvement not only in COVID-19 but also many other acute or chronic inflammatory diseases, both communicable and non-communicable. Here, we highlight the observed immune deviation of neutrophils in COVID-19 and summarize several promising therapeutic attempts to precisely target neutrophils and their reactivity in patients with COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据